19.15
0.43 (2.30%)
| Penutupan Terdahulu | 18.72 |
| Buka | 18.79 |
| Jumlah Dagangan | 451,305 |
| Purata Dagangan (3B) | 1,070,014 |
| Modal Pasaran | 1,532,299,904 |
| Harga / Jualan (P/S) | 12.86 |
| Harga / Buku (P/B) | 6.57 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | 3.86% |
| Margin Operasi (TTM) | 51.85% |
| EPS Cair (TTM) | 0.120 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7,882.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.21% |
| Nisbah Semasa (MRQ) | 5.61 |
| Aliran Tunai Operasi (OCF TTM) | 34.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 40.54 M |
| Pulangan Atas Aset (ROA TTM) | -0.40% |
| Pulangan Atas Ekuiti (ROE TTM) | 2.88% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Monte Rosa Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.63 |
|
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.73% |
| % Dimiliki oleh Institusi | 101.33% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |